N-cadherin inhibitor creates a microenvironment that protect TILs from immune checkpoints and Treg cells

Background Few patients with prostate cancer benefit from current immunotherapies. Therefore, we aimed to explore new strategies to change this paradigm.Methods Human tissues, cell lines and in vivo experiments were used to determine whether and how N-cadherin impacts the production of programmed de...

Full description

Bibliographic Details
Main Authors: Jun Jing, Yi Sun, Qiang Wei, Lu Yang, Huan Xu, Lingfan Xu, Hailiang Hu, Cai Tang, Shengzhuo Liu, Ruiqi Duan, Ju Guo
Format: Article
Language:English
Published: BMJ Publishing Group 2021-03-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/3/e002138.full